25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Artelo Biosciences Inc
Buy, Hold or Sell?

Let's analyze Artelo Biosciences Inc together

I guess you are interested in Artelo Biosciences Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Artelo Biosciences Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Artelo Biosciences Inc

I send you an email if I find something interesting about Artelo Biosciences Inc.

1. Quick Overview

1.1. Quick analysis of Artelo Biosciences Inc (30 sec.)










1.2. What can you expect buying and holding a share of Artelo Biosciences Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$1.97
Expected worth in 1 year
$-0.58
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
$-2.55
Return On Investment
-213.9%

For what price can you sell your share?

Current Price per Share
$1.19
Expected price per share
$1.31 - $1.5899
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Artelo Biosciences Inc (5 min.)




Live pricePrice per Share (EOD)
$1.19
Intrinsic Value Per Share
$-27.46 - $-32.00
Total Value Per Share
$-25.49 - $-30.02

2.2. Growth of Artelo Biosciences Inc (5 min.)




Is Artelo Biosciences Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$6.3m$16.9m-$8.2m-94.2%

How much money is Artelo Biosciences Inc making?

Current yearPrevious yearGrowGrow %
Making money-$2.2m-$2.3m$42.5k1.9%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Artelo Biosciences Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#659 / 925

Most Revenue
#851 / 925

Most Profit
#304 / 925

Most Efficient
#242 / 925
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Artelo Biosciences Inc?

Welcome investor! Artelo Biosciences Inc's management wants to use your money to grow the business. In return you get a share of Artelo Biosciences Inc.

First you should know what it really means to hold a share of Artelo Biosciences Inc. And how you can make/lose money.

Speculation

The Price per Share of Artelo Biosciences Inc is $1.19. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Artelo Biosciences Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Artelo Biosciences Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.97. Based on the TTM, the Book Value Change Per Share is $-0.64 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.57 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Artelo Biosciences Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.35-29.5%-0.71-59.4%-0.60-50.1%-0.55-46.6%-0.31-26.4%
Usd Book Value Change Per Share-0.29-24.4%-0.64-53.5%-0.57-47.7%0.021.5%0.054.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.29-24.4%-0.64-53.5%-0.57-47.7%0.021.5%0.054.1%
Usd Price Per Share1.12-1.34-2.17-1.45-1.86-
Price to Earnings Ratio-0.80--0.52--0.96--0.90--2.11-
Price-to-Total Gains Ratio-3.85--2.39--3.86--4.07--34.28-
Price to Book Ratio0.57-0.51-0.41-0.69--4.99-
Price-to-Total Gains Ratio-3.85--2.39--3.86--4.07--34.28-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.19
Number of shares840
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.640.02
Usd Total Gains Per Share-0.640.02
Gains per Quarter (840 shares)-534.6114.89
Gains per Year (840 shares)-2,138.4559.56
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-2138-214806050
20-4277-42860119110
30-6415-64240179170
40-8554-85620238230
50-10692-107000298290
60-12831-128380357350
70-14969-149760417410
80-17108-171140476470
90-19246-192520536530
100-21385-213900596590

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%0.041.00.00.0%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%3.017.00.015.0%10.029.01.025.0%11.029.01.026.8%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.041.00.0%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%3.017.00.015.0%10.029.01.025.0%11.029.01.026.8%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Artelo Biosciences Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.291-0.636+119%-0.567+95%0.018-1739%0.049-691%
Book Value Per Share--1.9712.707-27%5.258-63%3.869-49%1.9740%
Current Ratio--7.1548.394-15%19.254-63%17.339-59%10.229-30%
Debt To Asset Ratio--0.1090.102+6%0.048+127%0.065+67%0.767-86%
Debt To Equity Ratio--0.1220.115+6%0.050+143%0.071+72%0.390-69%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--2840669.5403331640.885-15%21107970.500-87%15169090.286-81%17388820.128-84%
Eps---0.351-0.706+101%-0.596+70%-0.555+58%-0.314-10%
Ev To Ebitda Ratio--infinfnan%4.643+inf%infnan%infnan%
Ev To Sales Ratio--infinfnan%infnan%infnan%infnan%
Free Cash Flow Per Share---0.241-0.649+169%-0.612+154%-0.502+108%-0.314+30%
Free Cash Flow To Equity Per Share---0.241-0.642+166%-0.657+173%-0.020-92%0.024-1109%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---31.996--------
Intrinsic Value_10Y_min---27.456--------
Intrinsic Value_1Y_max---2.581--------
Intrinsic Value_1Y_min---2.535--------
Intrinsic Value_3Y_max---8.231--------
Intrinsic Value_3Y_min---7.848--------
Intrinsic Value_5Y_max---14.456--------
Intrinsic Value_5Y_min---13.376--------
Market Cap3840963.000+6%3615669.5404309140.885-16%6987970.500-48%6092877.536-41%6724622.133-46%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio0.604+6%0.5680.512+11%0.406+40%0.687-17%-4.993+978%
Pe Ratio-0.848-6%-0.799-0.523-35%-0.965+21%-0.903+13%-2.114+165%
Price Per Share1.190+6%1.1201.335-16%2.165-48%1.447-23%1.861-40%
Price To Free Cash Flow Ratio-1.234-6%-1.162-0.632-46%-0.879-24%-1.023-12%-2.224+91%
Price To Total Gains Ratio-4.095-6%-3.855-2.386-38%-3.863+0%-4.073+6%-34.275+789%
Quick Ratio--0.7175.133-86%29.844-98%22.369-97%12.720-94%
Return On Assets---0.159-0.232+46%-0.130-18%-0.175+10%-0.669+322%
Return On Equity---0.178-0.258+45%-0.137-23%-0.190+7%-0.843+374%
Total Gains Per Share---0.291-0.636+119%-0.567+95%0.018-1739%0.049-691%
Usd Book Value--6361000.0008737250.000-27%16971750.000-63%13158124.500-52%6711747.550-5%
Usd Book Value Change Per Share---0.291-0.636+119%-0.567+95%0.018-1739%0.049-691%
Usd Book Value Per Share--1.9712.707-27%5.258-63%3.869-49%1.9740%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--2840669.5403331640.885-15%21107970.500-87%15169090.286-81%17388820.128-84%
Usd Eps---0.351-0.706+101%-0.596+70%-0.555+58%-0.314-10%
Usd Free Cash Flow---778000.000-2094750.000+169%-1976000.000+154%-1720560.300+121%-1014164.975+30%
Usd Free Cash Flow Per Share---0.241-0.649+169%-0.612+154%-0.502+108%-0.314+30%
Usd Free Cash Flow To Equity Per Share---0.241-0.642+166%-0.657+173%-0.020-92%0.024-1109%
Usd Market Cap3840963.000+6%3615669.5404309140.885-16%6987970.500-48%6092877.536-41%6724622.133-46%
Usd Price Per Share1.190+6%1.1201.335-16%2.165-48%1.447-23%1.861-40%
Usd Profit---1132000.000-2280250.000+101%-2322750.000+105%-1986193.100+75%-1108795.750-2%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.291-0.636+119%-0.567+95%0.018-1739%0.049-691%
 EOD+5 -3MRQTTM+17 -14YOY+16 -165Y+12 -1910Y+9 -22

3.3 Fundamental Score

Let's check the fundamental score of Artelo Biosciences Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.848
Price to Book Ratio (EOD)Between0-10.604
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.717
Current Ratio (MRQ)Greater than17.154
Debt to Asset Ratio (MRQ)Less than10.109
Debt to Equity Ratio (MRQ)Less than10.122
Return on Equity (MRQ)Greater than0.15-0.178
Return on Assets (MRQ)Greater than0.05-0.159
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Artelo Biosciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.021
Ma 20Greater thanMa 501.248
Ma 50Greater thanMa 1001.152
Ma 100Greater thanMa 2001.144
OpenGreater thanClose1.360
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Artelo Biosciences Inc

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Fundamental data was last updated by Penke on 2025-02-06 11:31:06.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Artelo Biosciences Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Artelo Biosciences Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Artelo Biosciences Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--100.3%+100.3%
TTM--211.5%+211.5%
YOY--213.8%+213.8%
5Y--346.2%+346.2%
10Y--489.2%+489.2%
4.3.1.2. Return on Assets

Shows how efficient Artelo Biosciences Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Artelo Biosciences Inc to the Biotechnology industry mean.
  • -15.9% Return on Assets means that Artelo Biosciences Inc generated $-0.16 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Artelo Biosciences Inc:

  • The MRQ is -15.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -23.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-15.9%TTM-23.2%+7.3%
TTM-23.2%YOY-13.0%-10.2%
TTM-23.2%5Y-17.5%-5.6%
5Y-17.5%10Y-66.9%+49.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-15.9%-12.0%-3.9%
TTM-23.2%-12.1%-11.1%
YOY-13.0%-11.4%-1.6%
5Y-17.5%-12.8%-4.7%
10Y-66.9%-14.6%-52.3%
4.3.1.3. Return on Equity

Shows how efficient Artelo Biosciences Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Artelo Biosciences Inc to the Biotechnology industry mean.
  • -17.8% Return on Equity means Artelo Biosciences Inc generated $-0.18 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Artelo Biosciences Inc:

  • The MRQ is -17.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -25.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-17.8%TTM-25.8%+8.0%
TTM-25.8%YOY-13.7%-12.2%
TTM-25.8%5Y-19.0%-6.8%
5Y-19.0%10Y-84.3%+65.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-17.8%-15.4%-2.4%
TTM-25.8%-16.2%-9.6%
YOY-13.7%-14.7%+1.0%
5Y-19.0%-18.6%-0.4%
10Y-84.3%-19.5%-64.8%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Artelo Biosciences Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Artelo Biosciences Inc is operating .

  • Measures how much profit Artelo Biosciences Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Artelo Biosciences Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Artelo Biosciences Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--201.5%+201.5%
TTM--313.4%+313.4%
YOY--215.2%+215.2%
5Y--371.8%+371.8%
10Y--492.1%+492.1%
4.3.2.2. Operating Ratio

Measures how efficient Artelo Biosciences Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Artelo Biosciences Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.139-2.139
TTM-3.198-3.198
YOY-3.358-3.358
5Y-4.842-4.842
10Y-6.500-6.500
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Artelo Biosciences Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Artelo Biosciences Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 7.15 means the company has $7.15 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Artelo Biosciences Inc:

  • The MRQ is 7.154. The company is very able to pay all its short-term debts. +2
  • The TTM is 8.394. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.154TTM8.394-1.241
TTM8.394YOY19.254-10.860
TTM8.3945Y17.339-8.945
5Y17.33910Y10.229+7.110
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.1543.610+3.544
TTM8.3943.871+4.523
YOY19.2544.609+14.645
5Y17.3395.977+11.362
10Y10.2296.216+4.013
4.4.3.2. Quick Ratio

Measures if Artelo Biosciences Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Artelo Biosciences Inc to the Biotechnology industry mean.
  • A Quick Ratio of 0.72 means the company can pay off $0.72 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Artelo Biosciences Inc:

  • The MRQ is 0.717. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 5.133. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ0.717TTM5.133-4.415
TTM5.133YOY29.844-24.711
TTM5.1335Y22.369-17.236
5Y22.36910Y12.720+9.648
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7173.085-2.368
TTM5.1333.360+1.773
YOY29.8444.400+25.444
5Y22.3695.972+16.397
10Y12.7206.483+6.237
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Artelo Biosciences Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Artelo Biosciences Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Artelo Biosciences Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.11 means that Artelo Biosciences Inc assets are financed with 10.9% credit (debt) and the remaining percentage (100% - 10.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Artelo Biosciences Inc:

  • The MRQ is 0.109. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.102. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.109TTM0.102+0.006
TTM0.102YOY0.048+0.055
TTM0.1025Y0.065+0.037
5Y0.06510Y0.767-0.702
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1090.341-0.232
TTM0.1020.343-0.241
YOY0.0480.315-0.267
5Y0.0650.363-0.298
10Y0.7670.384+0.383
4.5.4.2. Debt to Equity Ratio

Measures if Artelo Biosciences Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Artelo Biosciences Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 12.2% means that company has $0.12 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Artelo Biosciences Inc:

  • The MRQ is 0.122. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.115. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.122TTM0.115+0.007
TTM0.115YOY0.050+0.064
TTM0.1155Y0.071+0.044
5Y0.07110Y0.390-0.319
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1220.386-0.264
TTM0.1150.429-0.314
YOY0.0500.391-0.341
5Y0.0710.450-0.379
10Y0.3900.495-0.105
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Artelo Biosciences Inc generates.

  • Above 15 is considered overpriced but always compare Artelo Biosciences Inc to the Biotechnology industry mean.
  • A PE ratio of -0.80 means the investor is paying $-0.80 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Artelo Biosciences Inc:

  • The EOD is -0.848. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.799. Based on the earnings, the company is expensive. -2
  • The TTM is -0.523. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.848MRQ-0.799-0.050
MRQ-0.799TTM-0.523-0.276
TTM-0.523YOY-0.965+0.442
TTM-0.5235Y-0.903+0.380
5Y-0.90310Y-2.114+1.211
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.848-2.247+1.399
MRQ-0.799-2.706+1.907
TTM-0.523-3.253+2.730
YOY-0.965-3.392+2.427
5Y-0.903-6.132+5.229
10Y-2.114-6.735+4.621
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Artelo Biosciences Inc:

  • The EOD is -1.234. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.162. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.632. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.234MRQ-1.162-0.072
MRQ-1.162TTM-0.632-0.530
TTM-0.632YOY-0.879+0.247
TTM-0.6325Y-1.023+0.392
5Y-1.02310Y-2.224+1.201
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.234-3.026+1.792
MRQ-1.162-3.582+2.420
TTM-0.632-3.816+3.184
YOY-0.879-4.463+3.584
5Y-1.023-8.265+7.242
10Y-2.224-9.266+7.042
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Artelo Biosciences Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.57 means the investor is paying $0.57 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Artelo Biosciences Inc:

  • The EOD is 0.604. Based on the equity, the company is cheap. +2
  • The MRQ is 0.568. Based on the equity, the company is cheap. +2
  • The TTM is 0.512. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.604MRQ0.568+0.035
MRQ0.568TTM0.512+0.057
TTM0.512YOY0.406+0.106
TTM0.5125Y0.687-0.176
5Y0.68710Y-4.993+5.680
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.6041.948-1.344
MRQ0.5682.223-1.655
TTM0.5122.427-1.915
YOY0.4062.469-2.063
5Y0.6873.767-3.080
10Y-4.9934.507-9.500
4.6.2. Total Gains per Share

2.4. Latest News of Artelo Biosciences Inc

Does Artelo Biosciences Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Artelo Biosciences Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-02-14
15:00
Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex®Read

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Artelo Biosciences Inc.

4.8.1. Institutions holding Artelo Biosciences Inc

Institutions are holding 0.72% of the shares of Artelo Biosciences Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Geode Capital Management, LLC0.5375017350-2458-12.4091
2024-09-30Tower Research Capital LLC0.16060.00025183-640-10.9909
2024-09-30Bank of America Corp0.000802600
2024-09-30Morgan Stanley - Brokerage Accounts0.0006020-20-50
2024-09-30Rothschild Investment, LLC0.00020800
2024-09-30Citigroup Inc000-46-100
Total 0.69970.000222587-3164-14.0%

4.9.2. Funds holding Artelo Biosciences Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-12-31Fidelity Extended Market Index0.323501044300
2024-12-31NT Ext Equity Mkt Idx Fd - NL0.10330.0001333400
2024-12-31Fidelity Nasdaq Composite Index0.10080325300
2024-12-31Fidelity Series Total Market Index0.09440304800
2024-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.08190.00012643-44-1.6375
2024-12-31NT Ext Equity Mkt Idx Fd - L0.05680183200
2024-12-31Northern Trust Extended Eq Market Idx0.05680183200
2024-12-31State St US Extended Mkt Indx NL Cl C0.0215069300
2024-12-31Spartan Extended Market Index Pool E0.0188060600
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T30.013504374370
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T40.013504374370
2024-06-30SSgA U.S. Total Market Index Strategy0.008802848442
2024-09-30NT Ext Eq Mkt Indx Fd DC Lending Tier 50.0088028300
Total 0.90240.000229125+914+3.1%

5.3. Insider Transactions

Insiders are holding 0.828% of the shares of Artelo Biosciences Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2022-08-11Gregory D GorgasBUY12004.03
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets7,136
Total Liabilities775
Total Stockholder Equity6,361
 As reported
Total Liabilities 775
Total Stockholder Equity+ 6,361
Total Assets = 7,136

Assets

Total Assets7,136
Total Current Assets4,986
Long-term Assets2,150
Total Current Assets
Cash And Cash Equivalents 4,357
Short-term Investments 500
Other Current Assets 129
Total Current Assets  (as reported)4,986
Total Current Assets  (calculated)4,986
+/-0
Long-term Assets
Property Plant Equipment 108
Intangible Assets 2,039
Long-term Assets Other 3
Long-term Assets  (as reported)2,150
Long-term Assets  (calculated)2,150
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities697
Long-term Liabilities78
Total Stockholder Equity6,361
Total Current Liabilities
Accounts payable 627
Total Current Liabilities  (as reported)697
Total Current Liabilities  (calculated)627
+/- 70
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt112
Long-term Liabilities  (as reported)78
Long-term Liabilities  (calculated)112
+/- 34
Total Stockholder Equity
Total Stockholder Equity (as reported)6,361
Total Stockholder Equity (calculated)0
+/- 6,361
Other
Capital Stock3
Common Stock Shares Outstanding 3,228
Net Invested Capital 6,361
Net Working Capital 4,289
Property Plant and Equipment Gross 108



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-08-312015-06-302015-03-312014-09-302014-06-302014-03-312013-12-31
> Total Assets 
0
0
15
14
8
13
17
17
4
4
4
4
4
13
228
574
430
541
401
397
165
484
1,153
6,483
5,548
4,152
3,494
4,377
9,539
13,445
12,340
12,635
28,251
26,704
24,405
22,415
20,424
18,478
16,877
15,499
13,043
10,354
8,326
7,136
7,1368,32610,35413,04315,49916,87718,47820,42422,41524,40526,70428,25112,63512,34013,4459,5394,3773,4944,1525,5486,4831,15348416539740154143057422813444441717138141500
   > Total Current Assets 
0
0
15
14
8
13
17
17
4
4
4
4
4
13
228
574
429
540
400
396
165
484
1,152
4,443
3,508
2,111
1,453
2,337
7,500
11,405
10,300
10,317
24,609
24,589
22,282
20,303
18,322
16,386
14,602
13,428
10,980
8,188
6,168
4,986
4,9866,1688,18810,98013,42814,60216,38618,32220,30322,28224,58924,60910,31710,30011,4057,5002,3371,4532,1113,5084,4431,15248416539640054042957422813444441717138141500
       Cash And Cash Equivalents 
0
0
15
14
8
13
17
17
4
4
4
4
4
11
228
573
412
525
326
337
115
457
286
4,424
3,375
1,983
1,279
2,142
7,389
10,706
10,052
6,629
12,162
10,350
12,122
7,136
6,888
6,916
5,719
2,639
2,815
1,195
881
4,357
4,3578811,1952,8152,6395,7196,9166,8887,13612,12210,35012,1626,62910,05210,7067,3892,1421,2791,9833,3754,42428645711533732652541257322811444441717138141500
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
541
2
0
0
0
0
0
512
0
3,436
11,951
13,161
9,200
12,347
10,645
8,567
8,272
10,225
7,611
6,414
4,721
500
5004,7216,4147,61110,2258,2728,56710,64512,3479,20013,16111,9513,43605120000025410000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
16
22
3
9
7
9
46
30
0
0
0
0
0
0
0
1,999
0
0
0
0
0
0
0
0
0
0
00000000001,9990000000304697932216110000000000000000
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
3
0
2
16
14
58
37
46
18
859
10
88
99
173
195
111
187
248
252
514
3,077
2,949
2,308
789
903
611
10,789
554
579
566
129
12956657955410,7896119037892,3082,9493,0775142522481871111951739988108591846375814162030000000000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
0
0
1
2,040
2,040
2,041
2,041
2,040
2,040
2,040
2,039
2,318
3,642
2,115
2,123
2,112
2,102
2,092
2,275
2,068
2,063
2,166
2,158
2,150
2,1502,1582,1662,0632,0682,2752,0922,1022,1122,1232,1153,6422,3182,0392,0402,0402,0402,0412,0412,0402,04010011110000000000000000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
0
0
1
1
1
2
1
0
0
0
0
90
81
73
81
70
60
50
39
29
21
124
116
108
108116124212939506070817381900000121110011110000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,524
0
0
0
0
0
0
0
0
0
0
0
000000000001,52400000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,039
2,039
2,039
2,039
2,039
2,039
2,039
2,039
2,039
2,039
2,039
2,039
2,039
2,039
2,039
2,039
2,039
2,039
2,039
2,039
2,039
2,0392,0392,0392,0392,0392,0392,0392,0392,0392,0392,0392,0392,0392,0392,0392,0392,0392,0392,0392,0392,03900000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
189
3
3
3
3
0
0
197
3
0
0
0
0
000031970033331890000000000000000000000000000000
> Total Liabilities 
0
0
0
2
2
0
2
2
3
8
13
17
10
33
342
29
136
156
492
532
641
1,176
1,019
1,022
585
444
268
502
486
589
424
593
1,084
924
567
512
1,021
840
609
921
1,291
817
1,027
775
7751,0278171,2919216098401,0215125679241,0845934245894865022684445851,0221,0191,17664153249215613629342331017138322022000
   > Total Current Liabilities 
0
0
0
2
2
0
2
2
3
8
13
17
10
33
342
29
136
156
492
532
641
1,176
1,019
1,022
585
444
268
502
486
589
424
526
1,027
875
527
480
998
825
603
921
1,291
721
940
697
6979407211,2919216038259984805278751,0275264245894865022684445851,0221,0191,17664153249215613629342331017138322022000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
30
30
0
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
28
31
32
45
42
40
37
34
32
0
0
0
0
0000323437404245323128000000000000022030300000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000220000000000000000
       Accounts payable 
0
0
0
2
0
0
0
0
3
7
9
13
10
2
303
29
134
154
490
529
635
586
912
349
575
432
256
490
474
584
419
493
975
800
432
411
905
701
523
840
1,238
607
863
627
6278636071,238840523701905411432800975493419584474490256432575349912586635529490154134293032101397300002000
       Other Current Liabilities 
0
0
0
0
2
0
2
2
1
1
4
4
0
1
9
1
2
2
3
3
6
590
106
673
10
12
13
12
12
5
5
5
21
43
50
27
-852
-614
46
-791
0
0
0
0
0000-79146-614-852275043215551212131210673106590633221910441122020000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
3
7
9
13
10
32
333
29
134
154
490
529
635
586
912
349
575
432
256
490
474
584
419
67
57
49
40
32
23
15
6
0
0
96
87
78
788796006152332404957674195844744902564325753499125866355294901541342933332101397300000000
> Total Stockholder Equity
0
0
15
13
7
13
15
15
1
-4
-9
-14
-6
-19
-114
545
294
385
-91
-135
-475
-692
134
5,461
4,963
3,708
3,225
3,875
9,054
12,856
11,916
12,042
27,167
25,780
23,838
21,903
19,403
17,638
16,268
14,578
11,752
9,537
7,299
6,361
6,3617,2999,53711,75214,57816,26817,63819,40321,90323,83825,78027,16712,04211,91612,8569,0543,8753,2253,7084,9635,461134-692-475-135-91385294545-114-19-6-14-9-411515137131500
   Common Stock
0
0
6
6
6
7
8
8
8
8
8
8
8
8
10
11
11
12
13
14
14
16
2
3
3
3
4
5
15
22
23
25
42
42
42
3
3
3
3
3
0
0
0
0
00003333342424225232215543332161414131211111088888888766600
   Retained Earnings Total Equity00000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
-2
-12
-12
-7
-11
-10
-10
7
16
51
64
48
48
49
18
-18
-64
-176
-388
-254
-205
-201
-199
0
0
0
0
0000-199-201-205-254-388-176-64-18184948486451167-10-10-11-7-12-12-201000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,713
2,923
4,108
10,278
11,071
11,176
11,609
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000011,60911,17611,07110,2784,1082,9232,71300000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
24
24
24
32
38
38
39
39
39
39
56
56
56
828
855
1,587
1,869
2,502
3,203
3,616
4,108
10,278
11,071
11,176
11,609
13,272
19,891
25,574
26,859
28,902
48,081
48,705
49,324
49,970
50,675
51,029
51,254
52,011
0
0
0
0
000052,01151,25451,02950,67549,97049,32448,70548,08128,90226,85925,57419,89113,27211,60911,17611,07110,2784,1083,6163,2032,5021,8691,5878558285656563939393938383224242400



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.